DBV Technologies Q4 2024 Earnings Report

DBV Technologies EPS Results

• Actual EPS: -$1.10
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

DBV Technologies Revenue Results

• Actual Revenue: $0.51 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

DBV Technologies Announcement Details

• Quarter: Q4 2024
• Date: 4/11/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

DBV Technologies (NASDAQ:DBVT) SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents. Viaskin Peanut is being evaluated in global clinical trials to assess its ability to reduce allergic reactions and improve patients’ threshold of reactivity to peanut exposure. DBV is also exploring the applicability of its technologies to other food allergens, including cow’s milk and egg, as part of its long-term pipeline strategy.

Founded in 2002 and headquartered in Montrouge, France, DBV Technologies maintains research and development operations in Cambridge, Massachusetts, reflecting its transatlantic focus. The company has established alliances with academic institutions and leading allergy research centers to advance its clinical programs and expand its scientific expertise. Its development activities span North America, Europe and other regions where food allergy represents a significant public health challenge.

Under the leadership of President and Chief Executive Officer Daniel Tasse, DBV Technologies has navigated multiple phases of clinical development and regulatory interactions. The company continues to engage with health authorities to define approval pathways and to establish its proprietary immunotherapy platform as a new standard of care for allergic diseases.